Journal article

Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study.

Eliza Anne Hawkes, Kate Manos, Geoffrey Chong, Jodie Palmer, Michael Patrick MacManus, Colm Keane, Andrew Mark Scott, Jake Shortt, David Ritchie, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Anne Barraclough, Sze Ting Lee, Wendi Lin, Rachel Koldej, Richard Khor

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2020


TPS8075 Background: Most DLBCL & FL responds well to first line treatment, yet relapsed disease outcomes are poor. PD1/PDL1 inhibitors yield high response rates in some lymphomas, but single agent therapy in heavily pre-treated pts are disappointing. RT stimulates anti-tumor immunity through several mechanisms and may enhance response to immune checkpoint inhibition (ICI). Concurrent ICI & RT is synergistic in preclinical studies & solid tumors, improving local & distant (abscopal) response. RT to multiple disease sites may broaden the spectrum of tumor antigen release and overcome clonal variation between disease sites to further augment the immune response. Methods: RaDD (NCT03610061) is ..

View full abstract